Prevenção do Cancro do Colo do Útero
DOI:
https://doi.org/10.31877/on.2010.12.02Palavras-chave:
Cancro do colo do útero, prevenção do cancro do colo do útero, rastreio e vacinaçãoResumo
O cancro do colo do útero apresenta um importante impacto na vida das mulheres em todo o mundo, pois, embora o cancro seja mais frequente em pessoas idosas, o cancro do colo do útero afecta maioritariamente mulheres jovens, em idade activa, entre 35 e 50 anos, muitas das quais com responsabilidades profissionais e familiares. São reportados, anualmente, na União Europeia, cerca
de 34.000 novos casos e 16.000 mortes por cancro do colo do útero(1).
De todos os cancros, o cancro do colo do útero é o que apresenta um dos mais elevados potenciais de prevenção e cura, aquele que pode ser controlado com maior efectividade.
Na prevenção do cancro do colo do útero podem ser utilizadas estratégias de prevenção primária, através da vacinação, que tem como objectivo impedir a transmissão do agente (HPV-16 e -18), indispensável ao desenvolvimento da doença, e estratégias de prevenção secundária, através de um teste de rastreio (citologia ou teste de HPV), com o intuito de detectar as lesões pré-invasivas
e impedir o aparecimento de cancro.
Downloads
Referências
Arbyn M, European Commission. Directorate-General H, Consumer P. European guidelines for quality assurance in cervical cancer
screening. Luxembourg: Office for Official Publications of the European Communities; 2008.
Ferlay J, Bray F, Pisani P, Parkin DM. Cancer Incidence, Mortality and Prevalence Worldwide. GLOBOCAN 2002 IARC CancerBase No 5
version 20. 2004.
Franco EL, Duarte-Franco E, Ferenczy A. Cervical cancer: epidemiology, prevention and the role of human papillomavirus
infection. CMAJ. 2001 Apr 3;164(7):1017-25.
Registo Oncológico Nacional 2001 Instituto Português de Oncologia Francisco Gentil, Porto,2008.
Ferlay J. WHO Mortality Database Journal [serial on the Internet]. 2008 Date.
Tranbaloc P. [Natural history of precursor lesions of cervical cancer]. Gynecol Obstet Fertil. 2008 Jun;36(6):650-5.
Bosch FX, de Sanjose S. The epidemiology of human papillomavirus infection and cervical cancer. Dis Markers. 2007;23(4):213-27.
Bosch FX, Lorincz A, Munoz N, Meijer CJ, Shah KV. The causal relation between human papillomavirus and cervical cancer. J Clin
Pathol. 2002 Apr;55(4):244-65.
Weaver BA. Epidemiology and natural history of genital human papillomavirus infection. J Am Osteopath Assoc. 2006 Mar;106(3 Suppl 1):S2-8.
Baseman JG, Koutsky LA. The epidemiology of human papillomavirus infections. J Clin Virol. 2005 Mar;32 Suppl 1:S16-24.
Kufe D, Bast R, Hait W, Hong W, Polack R, Weichselbaum R, et al. Cancer Medicine 7. Hamilton, Ont.; Lewiston, NY [distributor]:
American Cancer Society BC Decker; 2006.
Munoz N, Bosch FX, de Sanjose S, Herrero R, Castellsague X, Shah KV, et al. Epidemiologic classification of human papillomavirus
types associated with cervical cancer. N Engl J Med. 2003 Feb 6;348(6):518-27.
de Villiers EM, Fauquet C, Broker TR, Bernard HU, zur Hausen H. Classification of papillomaviruses. Virology. 2004 Jun 20;324(1):17-27.
Miller AB, Nazeer S, Fonn S, Brandup-Lukanow A, Rehman R, Cronje H, et al. Report on consensus conference on cervical cancer screening and management. Int J Cancer. 2000 May 1;86(3):440-7.
The state of the art of cancer control structures in European countries in January 2008 Department of Hygiene and Epidemiology, Porto University Medical School, Portugal National Coordination for the Oncological Diseases, Portugal 2008.
Saslow D, Castle PE, Cox JT, Davey DD, Einstein MH, Ferris DG, et al. American Cancer Society Guideline for human papillomavirus (HPV) vaccine use to prevent cervical cancer and its precursors. CA Cancer J Clin. 2007 Jan-Feb;57(1):7-28.
Paavonen J, Jenkins D, Bosch FX, Naud P, Salmeron J, Wheeler CM, et al. Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial. Lancet. 2007 Jun 30;369(9580):2161-70.
Newall AT, Beutels P, Wood JG, Edmunds WJ, MacIntyre CR. Cost-effectiveness analyses of human papillomavirus vaccination. Lancet Infect Dis. 2007 Apr;7(4):289-96.
Joura EA, Leodolter S, Hernandez-Avila M, Wheeler CM, Perez G, Koutsky LA, et al. Efficacy of a quadrivalent prophylactic human papillomavirus (types 6, 11, 16, and 18) L1 virus-like-particle vaccine against high-grade vulval and vaginal lesions: a combined analysis of three randomised clinical trials. Lancet. 2007 May 19;369(9574):1693-702.
Harper DM, Franco EL, Wheeler CM, Moscicki AB, Romanowski B, Roteli-Martins CM, et al. Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial. Lancet. 2006 Apr 15;367(9518):1247-55.
Harper DM, Franco EL, Wheeler C, Ferris DG, Jenkins D, Schuind A, et al. Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial. Lancet. 2004 Nov 13-19;364(9447):1757-65.
Bosch FX, Castellsague X, de Sanjose S. HPV and cervical cancer: screening or vaccination? Br J Cancer. 2008 Jan 15;98(1):15-21.
Franco EL, Cuzick J, Hildesheim A, de Sanjose S. Chapter 20: Issues in planning cervical cancer screening in the era of HPV vaccination.
Vaccine. 2006 Aug 31;24 Suppl 3:S3/171-7.
Solomon D, Breen N, McNeel T. Cervical cancer screening rates in the United States and the potential impact of implementation
of screening guidelines. CA Cancer J Clin. 2007 Mar-Apr;57(2):105-11.
Nanda K, McCrory DC, Myers ER, Bastian LA, Hasselblad V, Hickey JD, et al. Accuracy of the Papanicolaou test in screening for and
follow-up of cervical cytologic abnormalities: a systematic review. Ann Intern Med. 2000 May 16;132(10):810-9.
Fahey MT, Irwig L, Macaskill P. Meta-analysis of Pap test accuracy. Am J Epidemiol. 1995 Apr 1;141(7):680-9.
Wright TC, Jr. Cervical cancer screening in the 21st century: is it time to retire the PAP smear? Clin Obstet Gynecol. 2007 Jun;50(2):313-23.
Sankaranarayanan R, Gaffikin L, Jacob M, Sellors J, Robles S. A critical assessment of screening methods for cervical neoplasia.
Int J Gynaecol Obstet. 2005 May;89 Suppl 2:S4-S12.
Cohn DE, Herzog TJ. New innovations in cervical cancer screening. Clin Obstet Gynecol. 2001 Sep;44(3):538-49.
Kitchener HC, Castle PE, Cox JT. Chapter 7: Achievements and limitations of cervical cytology screening. Vaccine. 2006 Aug 31;24
Suppl 3:S3/63-70.
Linder J, Zahniser D. The ThinPrep Pap test. A review of clinical studies. Acta Cytol. 1997 Jan-Feb;41(1):30-8.
Linder J, Zahniser D. ThinPrep Papanicolaou testing to reduce false-negative cervical cytology. Arch Pathol Lab Med. 1998 Feb;122(2):139-44.
Solomon D, Schiffman M, Tarone R. Comparison of three management strategies for patients with atypical squamous cells
of undetermined significance: baseline results from a randomized trial. J Natl Cancer Inst. 2001 Feb 21;93(4):293-9.
Wheeler CM, Hunt WC, Schiffman M, Castle PE. Human papillomavirus genotypes and the cumulative 2-year risk of cervical precancer. J Infect Dis. 2006 Nov 1;194(9):1291-9.
Sankaranarayanan R, Wesley R, Thara S, Dhakad N, Chandralekha B, Sebastian P, et al. Test characteristics of visual inspection with
% acetic acid (VIA) and Lugol’s iodine (VILI) in cervical cancer screening in Kerala, India. Int J Cancer. 2003 Sep 1;106(3):404-8.
Programas de rastreio da Região Norte. ARS Norte; 2009 [updated 2009; cited 23.07.2009]; Available from: http://portal.arsnorte.minsaude.pt/portal/page/portal/ARSNorte/Conte%C3%BAdos/Not%C3%ADcias/Programas%20de%20rastreio%20na%20Regi%C3%A3o%20Norte%20%20apresenta%C3%A7%C3%A3o.pdf.
IARC Handbooks on Cancer Prevention Cervix Cancer Screening. World Health Organization; 2005.
Engholm G, Ferlay, J. , Christensen, N., Bray, F.,Gjerstorff, ML., Klint,A., Køtlum, JE., Ólafsdóttir, E.,Pukkala, E., Storm, HA. . NORDCAN: Cancer Incidence, Mortality and Prevalence in the Nordic Countries, Version 3.4. Association of Nordic Cancer Registries. Danish Cancer Society. (http://www.ancr.nu). 2009 [cited.
Alves C AL, Lunet N. Prevalence and determinants of cervical cytology use in an urban sample of Portuguese women. Eur J Cancer Prev. 2009.
Downloads
Publicado
Como Citar
Edição
Secção
Licença
Direitos de Autor (c) 2023 Carla Alves dos Santos
Este trabalho encontra-se publicado com a Licença Internacional Creative Commons Atribuição-NãoComercial-CompartilhaIgual 4.0.
(CINAHL Ultimate database)
